业内人士指出，全球首创的分子设计（强PD-1+弱CD47融合蛋白）和突破性的安全性（解决CD47靶点血液毒性痛点），同时通过差异化临床策略避开红海竞争，聚焦未被满足的临床需求，HX009有望成为肿瘤免疫治疗领域的FIC，为免疫治疗耐药患者和罕见肿瘤患者带来新希望。

本综述系统阐述了抗CD47抗体修饰的顺铂负载介孔二氧化硅纳米颗粒（CDDP@MSN-Anti-CD47）在结直肠癌（CRC）治疗中的突破性进展。该研究创新性地将化疗药物顺铂（CDDP）与免疫检查点阻断剂抗CD47抗体整合于纳米载体，通过靶向递送诱导免疫原性细胞死亡（ICD）并 ...

本研究针对免疫性溶血后红细胞残骸清除机制不明的问题，通过体内外模型联合蛋白质组学分析，揭示了E3泛素连接酶MARCH1介导的CD47泛素化降解是促进巨噬细胞吞噬溶血红细胞的关键机制。该发现阐明了红细胞清除的新通路，为溶血相关疾病的治疗提供了潜在靶 ...

The effect of maintenance hormone therapy on overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study. This is an ASCO Meeting Abstract from the ...

CD47-null femoral fractures show reduced bone formation, but increased tissue mineral density. µCT analysis of transverse femoral fracture in WT (n = 9) and CD47-null (n = 11-14) mice at 10- and ...

“Together, these findings support a beneficial role for CD47 knockdown in alleviating age-associated metabolic dysfunction through coordinated effects across multiple organs” “Together, these findings ...

A characteristic of tumors includes the ability to avoid the immune system. In many cases tumors can progress without detection of immune cells. In the literature many scientists refer to undetectable ...

SEOUL, South Korea--(BUSINESS WIRE)--ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at ...

Risk of myelodysplastic syndrome and myeloproliferative neoplasms in patients with stable coronary artery disease and autoimmune conditions treated with colchicine. This is an ASCO Meeting Abstract ...